Baseline characteristics
| . | Apixaban (n = 128) . | Warfarin (n = 733) . | P . |
|---|---|---|---|
| Age, mean (±SD), y | 74 (±14) | 67 (±15) | <.01 |
| Female, n (%) | 74 (57.8) | 384 (52.4) | .256 |
| Comorbidities, n (%) | |||
| Heart failure | 68 (53.1) | 262 (35.7) | <.01 |
| Atrial fibrillation | 81 (63.3) | 216 (29.5) | <.01 |
| DVT/PE | 21 (14.4) | 235 (32.1) | <.01 |
| Hypertension | 57 (44.5) | 387 (52.8) | .086 |
| History of stroke | 16 (12.5) | 92 (12.6) | 1 |
| Myocardial infarction | 27 (21.1) | 167 (22.8) | .73 |
| History of bleeding | 8 (6.3) | 44 (6) | .84 |
| CABG | 13 (10.2) | 42 (4.7) | .08 |
| Diabetes | 44 (34.4) | 273 (37.2) | .55 |
| Hyperlipidemia | 57 (44.5) | 218 (29.7) | <.01 |
| Peripheral artery disease | 15 (11.7) | 58 (7.9) | .17 |
| History of smoking | 32 (25) | 120 (16.4) | .02 |
| History of falls | 5 (3.9) | 18 (2.5) | .37 |
| Hypercoagulable | 0 (0.0) | 9 (1.2) | .37 |
| Hemodialysis | 21 (16.4) | 118 (16.1) | .90 |
| Renal transplant | 0 (0) | 18 (2.5) | .09 |
| Liver disease | 13 (10.2) | 56 (7.6) | .38 |
| Laboratory values, median (IQR) | |||
| Study CrCl, mL/min | 18.7 (12.3,22.6) | 14.8 (10.1,19.5) | <.01 |
| Baseline INR | 1.2 (1.1,1.5) | 1.1 (1.1,1.2) | .03 |
| Baseline hemoglobin, g/dL | 10.2 (9.1,11.8) | 9.7 (8.5,11) | <.01 |
| Anticoagulation indication, n (%) | |||
| Atrial fibrillation/flutter | 71 (55.5) | 226 (30.8) | <.01 |
| History of atrial fibrillation | 26 (20.3) | 32 (4.4) | <.01 |
| Acute VTE | 20 (15.6) | 350 (47.7) | <.01 |
| Chronic VTE | 3 (2.3) | 7 (1) | .19 |
| Valve replacement | 0 (0) | 16 (2.2) | .09 |
| Cardiac thrombus | 2 (1.6) | 17 (2.3) | .55 |
| Other | 0 (0) | 40 (5.5) | .01 |
| Multiple | 6 (4.7) | 45 (6.1) | .48 |
| Concomitant agents, n (%) | |||
| Aspirin | 82 (64.1) | 473 (64.5) | .92 |
| Clopidogrel | 9 (7) | 86 (11.7) | .12 |
| Cilostazol | 7 (5.5) | 20 (2.7) | .10 |
| Ticagrelor | 1 (0.8) | 3 (0.4) | .48 |
| Apixaban dosing, n (%) | |||
| 2.5 mg twice daily | 73 (57) | ||
| 5 mg twice daily | 55 (43) | ||
| Incorrect dosing | 21 (16.4) | ||
| . | Apixaban (n = 128) . | Warfarin (n = 733) . | P . |
|---|---|---|---|
| Age, mean (±SD), y | 74 (±14) | 67 (±15) | <.01 |
| Female, n (%) | 74 (57.8) | 384 (52.4) | .256 |
| Comorbidities, n (%) | |||
| Heart failure | 68 (53.1) | 262 (35.7) | <.01 |
| Atrial fibrillation | 81 (63.3) | 216 (29.5) | <.01 |
| DVT/PE | 21 (14.4) | 235 (32.1) | <.01 |
| Hypertension | 57 (44.5) | 387 (52.8) | .086 |
| History of stroke | 16 (12.5) | 92 (12.6) | 1 |
| Myocardial infarction | 27 (21.1) | 167 (22.8) | .73 |
| History of bleeding | 8 (6.3) | 44 (6) | .84 |
| CABG | 13 (10.2) | 42 (4.7) | .08 |
| Diabetes | 44 (34.4) | 273 (37.2) | .55 |
| Hyperlipidemia | 57 (44.5) | 218 (29.7) | <.01 |
| Peripheral artery disease | 15 (11.7) | 58 (7.9) | .17 |
| History of smoking | 32 (25) | 120 (16.4) | .02 |
| History of falls | 5 (3.9) | 18 (2.5) | .37 |
| Hypercoagulable | 0 (0.0) | 9 (1.2) | .37 |
| Hemodialysis | 21 (16.4) | 118 (16.1) | .90 |
| Renal transplant | 0 (0) | 18 (2.5) | .09 |
| Liver disease | 13 (10.2) | 56 (7.6) | .38 |
| Laboratory values, median (IQR) | |||
| Study CrCl, mL/min | 18.7 (12.3,22.6) | 14.8 (10.1,19.5) | <.01 |
| Baseline INR | 1.2 (1.1,1.5) | 1.1 (1.1,1.2) | .03 |
| Baseline hemoglobin, g/dL | 10.2 (9.1,11.8) | 9.7 (8.5,11) | <.01 |
| Anticoagulation indication, n (%) | |||
| Atrial fibrillation/flutter | 71 (55.5) | 226 (30.8) | <.01 |
| History of atrial fibrillation | 26 (20.3) | 32 (4.4) | <.01 |
| Acute VTE | 20 (15.6) | 350 (47.7) | <.01 |
| Chronic VTE | 3 (2.3) | 7 (1) | .19 |
| Valve replacement | 0 (0) | 16 (2.2) | .09 |
| Cardiac thrombus | 2 (1.6) | 17 (2.3) | .55 |
| Other | 0 (0) | 40 (5.5) | .01 |
| Multiple | 6 (4.7) | 45 (6.1) | .48 |
| Concomitant agents, n (%) | |||
| Aspirin | 82 (64.1) | 473 (64.5) | .92 |
| Clopidogrel | 9 (7) | 86 (11.7) | .12 |
| Cilostazol | 7 (5.5) | 20 (2.7) | .10 |
| Ticagrelor | 1 (0.8) | 3 (0.4) | .48 |
| Apixaban dosing, n (%) | |||
| 2.5 mg twice daily | 73 (57) | ||
| 5 mg twice daily | 55 (43) | ||
| Incorrect dosing | 21 (16.4) | ||
aPTT, activated partial thromboplastin time; CABG, coronary artery bypass graft; INR, international normalized ratio; TIA, transient ischemic stroke.